Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Pegasys Has 23% Market Share; Better Luck In Rematch With Intron? 

Executive Summary

Roche's Pegasys has captured a 23% share of new prescriptions for hepatitis C in the U.S., Global Pharmaceutical Head William Burns told investors during a year-end conference in London Feb. 26

You may also be interested in...



Pegasys Catching Up To PEG-Intron; Schering Admits “Complacency”

Schering-Plough plans to focus more directly on maintaining market share in the pegylated interferon market after losing about one-third of its share to Roche, Global Pharmaceuticals President Carrie Cox told a July 23 conference call

Pegasys Catching Up To PEG-Intron; Schering Admits “Complacency”

Schering-Plough plans to focus more directly on maintaining market share in the pegylated interferon market after losing about one-third of its share to Roche, Global Pharmaceuticals President Carrie Cox told a July 23 conference call

Schering Global Pharma President Cox To Tackle Flagging Allergy Sales

The first priority for Schering-Plough's new Global Pharmaceutical President Carrie Cox will be implementing marketing changes for the company's allergy franchise

Related Content

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel